Diagnostic Mycology Laboratories Should Have a Central Role for the Management of Fungal Disease

J Fungi (Basel). 2022 Dec 8;8(12):1285. doi: 10.3390/jof8121285.

Abstract

The absence of awareness of fungal diseases as part of the differential diagnosis in at-risk populations has severe consequences. Here, we show how the active role of laboratories can improve patients’ survival. Recently, major advances have been made in non-culture-based assays for fungal diseases, improving accuracy and turnaround time. Furthermore, with the introduction of proficiency control systems, laboratories are an easily monitored environment with good analytical accuracy. Diagnostic packages for opportunistic infections can overcome many deficiencies caused by the absence of awareness. In Guatemala, to make diagnosis accessible, we set up a diagnostic laboratory hub (DLH) providing screening for cryptococcosis, histoplasmosis and tuberculosis to a network of 13 healthcare facilities attending people living with HIV (PLWHIV). In two years, we screened 2127 newly HIV-diagnosed patients. The frequency of opportunistic infections was 21%, rising to 30.3% in patients with advanced HIV disease (<200 CD4); 8.1% of these patients had more than one infection. With the implementation of this diagnostic package, mortality decreased by 7%, a key goal of many public health interventions. Screening for serious infection in high-risk populations can partially overcome training or experiential deficiencies among clinicians for life-threatening fungal diseases.

Keywords: HIV; Latin America; cryptococcosis; histoplasmosis; opportunistic infections; public health; tuberculosis.

Grants and funding

The program implemented in Guatemala was supported by Global Action for Fungal Infections and JYLAG, a charity foundation based in Switzerland (E.A. received this funding under the proposal: “Minimizing HIV deaths through rapid fungal diagnosis and better care in Guatemala”).